Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study.

@article{Yamasaki1997LongtermHD,
  title={Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study.},
  author={Kazutomo Yamasaki and Jun-ichi Kira and Yoshio Koyanagi and Yuji Kawano and Naoko Miyano-Kurosaki and Minoru Nakamura and Eishi Baba and Junji Suzuki and Akira Yamamoto and Naoki Yamamoto and Tomoo Kobayashi},
  journal={Journal of the neurological sciences},
  year={1997},
  volume={147 2},
  pages={135-44}
}
The efficacy of long-term, high dose interferon-alpha (IFN-alpha) therapy was studied in seven patients with HTLV-I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP). IFN-alpha was administered at a dose of 6 x 10(6) international units daily for the initial 2 weeks and thereafter 3 times a week for the following 22 weeks. Five patients showed a sustained improvement in motor performance during and up to 6 months after the completion of IFN-alpha. The other patient who responded to… CONTINUE READING
16 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…